LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

LLY

967.2

+2.07%↑

JNJ

220.59

-0.24%↓

ABBV

202.7

+0.78%↑

UNH

381.52

+0.55%↑

AZN

182.17

-0.08%↓

Inicio・Lista de Acciones・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Abierto

SectorSanidad

49.18 -4.47

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

49.37

Máximo

51.64

Métricas clave
By Trading Economics
Ingresos	6.6M -39M
Ventas	19M 212M
P/B Media del Sector	48.435 49.8
BPA	0.882
Margen de beneficios	-18.221
Empleados	778
EBITDA	127M 90M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+22.59% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-106M 2.8B
Apertura anterior	53.65
Cierre anterior	49.18

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

86 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

31.35 / 32.36 Soporte y Resistencia

Supernus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 may 2026, 23:47 UTC

Charlas de Mercado

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 may 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 may 2026, 23:38 UTC

Charlas de Mercado

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 may 2026, 23:14 UTC

Charlas de Mercado

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 may 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 may 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 may 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 may 2026, 10:21 UTC

Ganancias

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 may 2026, 06:05 UTC

Ganancias

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 may 2026, 23:55 UTC

Ganancias

Review & Preview: Still Going Strong -- Barrons.com

8 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 20:49 UTC

Ganancias

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 may 2026, 20:25 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 may 2026, 19:43 UTC

Ganancias

Cencosud 1Q Net $115M

8 may 2026, 19:20 UTC

Charlas de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 may 2026, 19:18 UTC

Ganancias

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 may 2026, 19:16 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:08 UTC

Ganancias

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 may 2026, 19:05 UTC

Ganancias

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 may 2026, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 may 2026, 18:51 UTC

Ganancias

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 may 2026, 18:49 UTC

Ganancias

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 may 2026, 18:41 UTC

Ganancias

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 may 2026, 17:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 may 2026, 17:14 UTC

Ganancias

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 may 2026, 17:04 UTC

Charlas de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Supernus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

22.59% repunte

Estimación a 12 Meses

Media 63.17 USD 22.59%

Máximo 66 USD

Mínimo 55 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Supernus Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

31.35 / 32.36Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

86 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.